David Ferraro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
David Ferraro has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Anthony R. Cillo
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
44 shared publications - Elina Mukherjee
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
44 shared publications - Jessica D. Daley
University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
44 shared publications - Kelly M. Bailey
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
44 shared publications - Shanthi Bhaskar
Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
44 shared publications - Tullia C. Bruno
Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
44 shared publications
Latest Publications
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S3. Correlation between tumor response and fold change in immune cell infiltration.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S3. Correlation between tumor response and fold change in immune cell infiltration.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S8 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S8. Differentially expressed genes in Ewing sarcoma tumor cells associated with each cellular neighborhood.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S8 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S8. Differentially expressed genes in Ewing sarcoma tumor cells associated with each cellular neighborhood.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S1. NKX2.2 staining in Ewing tumor TMA samples.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S1. NKX2.2 staining in Ewing tumor TMA samples.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S4. Enrichment of immunosuppressive proteins occurs in the Ewing TME following treatment with pembrolizumab.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S4. Enrichment of immunosuppressive proteins occurs in the Ewing TME following treatment with pembrolizumab.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S6. Identification of groups of patients based on the frequency of spatially resolved cellular neighborhoods.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S6. Identification of groups of patients based on the frequency of spatially resolved cellular neighborhoods.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S9. HLA class I expression is modifiable and upregulated in Ewing sarcoma cells following interferon-gamma (IFNγ) treatment.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S9. HLA class I expression is modifiable and upregulated in Ewing sarcoma cells following interferon-gamma (IFNγ) treatment.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S7. Spatial distribution of cells from each patient tumor biopsy and enumeration of the proportion of cells with in each spatially resolved cell neighborhoods in each biopsy.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S7. Spatial distribution of cells from each patient tumor biopsy and enumeration of the proportion of cells with in each spatially resolved cell neighborhoods in each biopsy.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S2. Quantification of immune cell subsets utilizing multiplex immunohistochemistry.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S2. Quantification of immune cell subsets utilizing multiplex immunohistochemistry.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S5. Correlations between protein levels in stroma at baseline and changes in tumor size from pre- to post-treatment.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Figure S5. Correlations between protein levels in stroma at baseline and changes in tumor size from pre- to post-treatment.
- Open Access
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Table S1. Proteins included in the Nanostring GeoMx immuno-oncology panel.
- 2 September 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from SARC028 Samples Reveal an Interplay between TGF-β, IFN Signaling, and Low HLA Class I Expression as Contributors to Ewing Sarcoma Checkpoint Blockade Resistance
Supplementary Table S1. Proteins included in the Nanostring GeoMx immuno-oncology panel.